NLTX Annual FCF
-$46.72 M
+$4.10 M+8.08%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual free cash flow is -$46.72 million, with the most recent change of +$4.10 million (+8.08%) on December 31, 2022. During the last 3 years, it has fallen by -$30.44 million (-187.08%).NLTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly FCF
-$4.27 M
-$88.00 K-2.10%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly free cash flow is -$4.27 million, with the most recent change of -$88.00 thousand (-2.10%) on September 30, 2023. Over the past year, it has increased by +$5.34 million (+55.58%).NLTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM FCF
-$32.94 M
+$5.34 M+13.95%
30 September 2023
Summary:
As of February 5, 2025, NLTX TTM free cash flow is -$32.94 million, with the most recent change of +$5.34 million (+13.95%) on September 30, 2023. Over the past year, it has increased by +$15.30 million (+31.72%).NLTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.1% | +55.6% | +31.7% |
| 3 y3 years | -187.1% | -612.7% | -47.5% |
| 5 y5 years | -3.3% | +72.2% | -102.4% |
NLTX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +545.4% | -146.6% | +3554.6% |
Neoleukin Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$4.27 M(+2.1%) | -$32.94 M(-14.0%) |
| June 2023 | - | -$4.18 M(-68.9%) | -$38.28 M(-16.1%) |
| Mar 2023 | - | -$13.45 M(+21.9%) | -$45.63 M(-2.3%) |
| Dec 2022 | -$46.72 M(-8.1%) | -$11.04 M(+14.8%) | -$46.72 M(-3.2%) |
| Sept 2022 | - | -$9.61 M(-16.6%) | -$48.24 M(+0.6%) |
| June 2022 | - | -$11.53 M(-20.7%) | -$47.98 M(-5.8%) |
| Mar 2022 | - | -$14.54 M(+15.8%) | -$50.92 M(+0.2%) |
| Dec 2021 | -$50.82 M(+89.7%) | -$12.56 M(+34.5%) | -$50.82 M(+5.6%) |
| Sept 2021 | - | -$9.34 M(-35.4%) | -$48.14 M(+22.2%) |
| June 2021 | - | -$14.47 M(+0.1%) | -$39.40 M(+13.5%) |
| Mar 2021 | - | -$14.45 M(+46.2%) | -$34.69 M(+29.5%) |
| Dec 2020 | -$26.79 M(+64.7%) | -$9.88 M(+1549.7%) | -$26.79 M(+20.0%) |
| Sept 2020 | - | -$599.00 K(-93.9%) | -$22.33 M(-21.3%) |
| June 2020 | - | -$9.77 M(+49.2%) | -$28.36 M(+41.3%) |
| Mar 2020 | - | -$6.55 M(+20.8%) | -$20.06 M(+23.3%) |
| Dec 2019 | -$16.27 M(-48.5%) | -$5.42 M(-18.3%) | -$16.27 M(-21.1%) |
| Sept 2019 | - | -$6.63 M(+351.0%) | -$20.63 M(-29.8%) |
| June 2019 | - | -$1.47 M(-46.7%) | -$29.38 M(+56.6%) |
| Mar 2019 | - | -$2.76 M(-71.8%) | -$18.75 M(-40.7%) |
| Dec 2018 | -$31.63 M | -$9.78 M(-36.4%) | -$31.63 M(-5.5%) |
| Sept 2018 | - | -$15.37 M(-268.0%) | -$33.47 M(+12.9%) |
| June 2018 | - | $9.15 M(-158.6%) | -$29.65 M(-40.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$15.63 M(+34.5%) | -$49.45 M(+9.4%) |
| Dec 2017 | -$45.21 M(+46.1%) | -$11.62 M(+0.6%) | -$45.21 M(+5.9%) |
| Sept 2017 | - | -$11.56 M(+8.5%) | -$42.69 M(+9.8%) |
| June 2017 | - | -$10.65 M(-6.5%) | -$38.87 M(+6.7%) |
| Mar 2017 | - | -$11.39 M(+25.2%) | -$36.43 M(+17.7%) |
| Dec 2016 | -$30.94 M(+52.5%) | -$9.09 M(+17.5%) | -$30.94 M(+19.9%) |
| Sept 2016 | - | -$7.74 M(-5.7%) | -$25.81 M(+13.7%) |
| June 2016 | - | -$8.21 M(+39.2%) | -$22.70 M(+14.1%) |
| Mar 2016 | - | -$5.90 M(+48.7%) | -$19.89 M(-2.0%) |
| Dec 2015 | -$20.29 M(+15.3%) | -$3.97 M(-14.1%) | -$20.29 M(-11.9%) |
| Sept 2015 | - | -$4.62 M(-14.4%) | -$23.05 M(+1.9%) |
| June 2015 | - | -$5.40 M(-14.4%) | -$22.63 M(+12.6%) |
| Mar 2015 | - | -$6.31 M(-6.2%) | -$20.10 M(+14.2%) |
| Dec 2014 | -$17.60 M(+124.7%) | -$6.72 M(+60.0%) | -$17.60 M(+20.4%) |
| Sept 2014 | - | -$4.20 M(+46.3%) | -$14.62 M(+20.2%) |
| June 2014 | - | -$2.87 M(-24.6%) | -$12.17 M(+13.3%) |
| Mar 2014 | - | -$3.81 M(+1.7%) | -$10.74 M(+37.1%) |
| Dec 2013 | -$7.83 M(+8.2%) | -$3.74 M(+114.6%) | -$7.83 M(+91.5%) |
| Sept 2013 | - | -$1.74 M(+20.8%) | -$4.09 M(+74.4%) |
| June 2013 | - | -$1.44 M(+60.2%) | -$2.35 M(+160.2%) |
| Mar 2013 | - | -$901.30 K | -$901.30 K |
| Dec 2012 | -$7.24 M | - | - |
FAQ
- What is Neoleukin Therapeutics annual free cash flow?
- What is the all time high annual FCF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual FCF year-on-year change?
- What is Neoleukin Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly FCF year-on-year change?
- What is Neoleukin Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM FCF year-on-year change?
What is Neoleukin Therapeutics annual free cash flow?
The current annual FCF of NLTX is -$46.72 M
What is the all time high annual FCF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual free cash flow is -$7.24 M
What is Neoleukin Therapeutics annual FCF year-on-year change?
Over the past year, NLTX annual free cash flow has changed by +$4.10 M (+8.08%)
What is Neoleukin Therapeutics quarterly free cash flow?
The current quarterly FCF of NLTX is -$4.27 M
What is the all time high quarterly FCF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly free cash flow is $9.15 M
What is Neoleukin Therapeutics quarterly FCF year-on-year change?
Over the past year, NLTX quarterly free cash flow has changed by +$5.34 M (+55.58%)
What is Neoleukin Therapeutics TTM free cash flow?
The current TTM FCF of NLTX is -$32.94 M
What is the all time high TTM FCF for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM free cash flow is -$901.30 K
What is Neoleukin Therapeutics TTM FCF year-on-year change?
Over the past year, NLTX TTM free cash flow has changed by +$15.30 M (+31.72%)